Venetoclax and Hypomethylating Agent in Previously Untreated Higher-Risk Myelodysplastic Syndromes and Genotype Signatures for Response and Prognosis: A Real-World Study
Am J Hematol. 2024 Nov 22.
doi: 10.1002/ajh.27532.
Online ahead of print.
1 Peking University People's Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.
2 Department of Hematology, Beijing Qinghe Hospital, Beijing, China.
3 Center for Life Sciences, Peking-Tsinghua Center for Life Sciences, Beijing, China.
4 Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.